Locations:
Min Investment:
Max Investment:
Target Investment:
2014
Drug Discovery using large-scale selection experiments and structure- and AI-based software to create novel biologics. Founding CEO focused on business development, fundraising (over $28M from leading US and Asia investors), target selection and research strategy, technical strategy including algorithms and AI tools in biology.
2022
2022
Consortium to advance AI in Biomedical Research. Founded in 2022 by Arzeda, Cyrus, Outpace, Prescient/Genentech with support from Amazon Web Services and other tech partners. Our first release with Mohammed AlQuraishi's lab at Columbia is the OpenFold structure prediction software, more projects in protein language models, GPU-enabled physics based models, and more to come. Protein structure prediction, design, modeling using AI.
2022
Early stage investing focused on the intersection of biotechnology and digital technology.
2008 - 2015
2014 - 2015
Software development and market research / customer development aimed at launching an easy-to-use version of Rosetta. This work formed the basis of Cyrus Bench and internal Cyrus software infrastructure for protein engineering software.
2008 - 2014
Baker Lab, Computational Enzyme Design. Biochemistry lab and software lab work in organocatalysis (Morita Baylis Hillman reaction and covalent catalysis), enzymes for fluorescent labeling in cell biology, protein stabilization. Algorithm development in protein design for enzyme activity, protein stabilization.
2012 - 2015
2012 - 2015
Started PedalAnywhere, a new concept in web-enabled long-term bike rental, with co-founder Zach Shaner. We sold the company to a combination of employees and investors and they are continuing to grow this unique transportation business.
2003 - 2007
2003 - 2007
Cabot House, Fellowships advising (Rhodes, Marshall, Fulbright, etc.), graduate school advising.
2001 - 2002
2001 - 2002
Lab of Kurt Wuthrich, solved the Feline (cat) prion protein structure by NMR.